Martin Currie Ltd. Sells 15,646 Shares of ResMed Inc. (NYSE:RMD)

Martin Currie Ltd. trimmed its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 12.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,881 shares of the medical equipment provider's stock after selling 15,646 shares during the period. Martin Currie Ltd. owned 0.08% of ResMed worth $26,272,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its position in shares of ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 110 shares during the last quarter. OFI Invest Asset Management acquired a new stake in ResMed during the 4th quarter valued at $39,000. BankPlus Trust Department bought a new position in ResMed during the fourth quarter worth $44,000. Rosenberg Matthew Hamilton acquired a new position in shares of ResMed in the fourth quarter valued at $54,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of ResMed in the fourth quarter valued at about $67,000. 54.98% of the stock is owned by institutional investors.

Insider Transactions at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $229.20, for a total transaction of $1,835,662.80. Following the sale, the chief executive officer now owns 455,472 shares of the company's stock, valued at approximately $104,394,182.40. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares of the company's stock, valued at $2,327,289.75. The trade was a 50.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,940 shares of company stock valued at $9,164,385. Corporate insiders own 0.71% of the company's stock.

Remove Ads

ResMed Price Performance

ResMed stock traded down $1.71 during trading hours on Tuesday, reaching $222.14. 766,886 shares of the stock were exchanged, compared to its average volume of 1,000,387. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a twelve month low of $172.19 and a twelve month high of $263.05. The company has a market cap of $32.62 billion, a P/E ratio of 26.23, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. The stock has a 50 day moving average of $233.37 and a two-hundred day moving average of $237.83.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Equities analysts expect that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a $0.53 dividend. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed's payout ratio is 25.03%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, March 25th. UBS Group raised ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. JPMorgan Chase & Co. upped their price objective on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Finally, Morgan Stanley began coverage on ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $249.73.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.